Lipocine Inc

NASDAQ:LPCN   3:59:53 PM EDT
1.32
-0.02 (-1.49%)
Products

FDA Clears LPCN 1154 IND Application For A Phase 2 Postpartum Depression Study

Published: 06/14/2021 12:41 GMT
Lipocine Inc (LPCN) - FDA Clears Lpcn 1154 Ind Application for a Phase 2 Postpartum Depression Study.
Lipocine - Pharmacokinetic Study to Assess Dose Proportionality is Planned to Start in July 2021 With Top-line Results Expected in Q3 of 2021.